ELITE PHARMACEUTICALS, INC /NV/— Sankey Diagram

Annual mode · period ending 2025-12-31 · SEC EDGAR

FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$126M
↑+39.3% +$36Mvs FY2024
Total Liabilities
$46M
↓-15.1% -$8Mvs FY2024
Equity
$80M
↑+120.4% +$44Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the annual mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025FY2024
Total Assets$126M$91M
Current Assets$97M$48M
Cash$0$0
ST Investments$0$0
Receivables$49M$18M
Inventory$25M$20M
Other Current$23M$9M
Non-Current Assets$30M$43M
PPE$10M$10M
Goodwill$0$0
Intangibles$6M$7M
Investments$0$0
Other Non-Current$14M$26M
Total Liab+Eq$126M$91M
Current Liab.$13M$15M
Accounts Payable$7M$6M
Short-Term Debt$0$0
Deferred Revenue$0$9K
Other CL$7M$9M
Non-Current Liab.$33M$40M
Long-Term Debt$0$0
Other LT Liab.$33M$40M
Equity$80M$36M
Retained Earnings$94M$138M
Other Equity$0$0

QuarterCharts · SEC EDGAR data · ELTP · Comparing FY2025 vs FY2024